Business Wire

MA-BVI

4.10.2021 14:03:01 CEST | Business Wire | Press release

Share
BVI Announces Investment & Collaboration with Beyeonics Vision

BVI , a purpose-built diversified global ophthalmic device company, today announced an investment in Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT) ("Elbit Systems"). Beyeonics Vision uses integrated augmented reality, tracking, and image processing/AI platforms to deliver improved visualization, optimized workflow, and real-time support to surgeon decision-making process in the operating room. The collaboration also promotes a streamlined process to commercialize Beyeonics™ One in the United States, with potential for rapid expansion in territories outside of the United States.

“BVI routinely assesses opportunities to partner with companies that have a commitment to innovation and share our entrepreneurial mindset. With Beyeonics One, BVI can expand our offering of unparalleled surgical experience during anterior and posterior segment procedures,” said Shervin Korangy, BVI’s President and Chief Executive Officer. “We know from experience that it takes shared priorities to deliver on our mission and are excited that Beyeonics Vision shares our passion for and commitment to refocusing the future of vision.”

Beyeonics Vision has been developing Beyeonics One, the first and only commercial ophthalmic digital imaging system to replace optical analog microscopes. Beyeonics One is an open and upgradable digital visualization platform, equipped with an ultra-high-resolution camera that processes and transfers digitally enhanced images to a high-resolution head-wearable display for a truly immersive and natural stereoscopic 3-D viewing experience. Beyeonics One provides surgeons with enhanced automation, programming autonomy and more freedom to set-up the operating room and adopt a more ergonomically efficient posture. Additionally, the system enables real-time decision-making process with customizable integration of accessible pre-/intra-operative data and seamless integration with other devices.

“We are excited to partner with BVI on the U.S. commercialization of Beyeonics One and the potential to collaborate on future innovations as well. Through this collaboration we aim to expand our collective capabilities to optimize all aspects of visualization for eye surgeons and offer a transformative experience to providers and patients,” shared Ron Schneider, CEO of Beyeonics Vision.

BVI first previewed their partnership with Beyeonics Vision at the American Society of Cataract and Refractive Surgery annual meeting in July 2021 and will continue this at ESCRS in Amsterdam in October, & AAO in New Orleans in November.

About BVI

BVI® is a global ophthalmic medical device manufacturer with a mission to deliver high quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams, in more than 115 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).

About Beyeonics Vision

Beyeonics™ Vision, a subsidiary from Elbit Systems (NASDAQ:ESLT), is a medical technology company developing surgeon-centered visualization solutions. Beyeonics is aiming to consolidate & democratize surgery, deliver a transformative technology by using integrated augmented reality, tracking and image processing visualization platform to tell surgeons valuable information, to guide decisions and to perform automatic tasks.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release

Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release

Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release

Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be

From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release

Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye